Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue Estimates
Alumis Inc. ALMS
$6.60
▲ +0.76%
(+$0.05)
📅 Earnings This Week
Open
$6.54
Prev Close
$6.55
Day Range
$6.41 – $6.68
52W Range
$4.40 – $31.35
Market Cap
$874.39M
Beta
1.69
EPS (TTM)
$-3.81
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-06-28 |
| Shares Out. | 129,440,000 |
| Website | alumis.com/ ↗ |
| Phone | 13025310855 |
| Employees | 239 |
| Revenue | $1.7M |
| Gross Profit | $1.7M |
| Net Income | -$142.2M |
| Free Cash Flow | -$351.8M |
| Total Assets | $560.6M |
| Total Liabilities | $108.5M |
| Equity | $452.2M |
About Alumis Inc.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Alumis Inc. is a publicly traded company under the ticker symbol ALMS on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-11-01)